Physician profile
Russell Abrams
NPI 1114956505
$10,956.67
in general payments reported to CMS, 2019-2025
36 companies · $2,211 in 2025
The $2,211 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,749 · 2020: $3,993 · 2021: $24.10 · 2022: $162 · 2023: $1,438 · 2024: $1,379 · 2025: $2,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,928 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,928.45 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,645.79 | 2020 | |
| Abbvie INC. | $2,116.27 | 2023-2025 | Ubrelvy, Qulipta, Botox |
| Teva Pharmaceuticals USA, INC. | $1,250.53 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Pfizer INC. | $673.32 | 2023-2025 | |
| Amgen INC. | $575.62 | 2019-2020 | |
| Lilly USA, LLC | $281.49 | 2019-2024 | Emgality |
| Boston Scientific Corporation | $233.81 | 2019-2025 | General - Therapies, Ams 700, Wavewriter Alpha Prime 16 |
| Nevro Corp. | $191.94 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $175.00 | 2023 | Ingrezza, Ongentys |
| Impel Pharmaceuticals INC. | $160.56 | 2023 | Trudhesa |
| Currax Pharmaceuticals LLC | $152.81 | 2025 | Onzetra Xsail, Contrave |
| Providence Medical Technology, INC. | $149.82 | 2022 | |
| Vertos Medical, INC. | $147.85 | 2023 | Mild Device Kit |
| Saluda Medical Americas, INC. | $136.23 | 2025 | Evoke |
| Corium, LLC | $124.99 | 2023 | Azstarys |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $124.98 | 2024 | Sprint Pns System |
| Spinal Simplicity, LLC | $112.73 | 2024 | Ha Minuteman G3-R |
| Impel Pharmaceuticals LLC | $85.56 | 2025 | Trudhesa |
| Emd Serono, INC. | $74.26 | 2019-2021 | |
| Pacira Therapeutics, INC. | $64.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $61.24 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $54.55 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.11 | 2019 | |
| Supernus Pharmaceuticals, INC. | $44.64 | 2019-2020 | |
| Mdd US Operations, LLC | $42.78 | 2019-2020 | |
| Assertio Therapeutics, INC. | $40.28 | 2019 | |
| Shire North American Group INC | $29.06 | 2019 | |
| Shionogi INC | $27.25 | 2019 | |
| Collegium Pharmaceutical, INC. | $23.54 | 2019 | |
| Amneal Pharmaceuticals LLC | $17.30 | 2025 | Crexont |
| Acorda Therapeutics, INC | $14.69 | 2019 | |
| Scilex Pharmaceuticals INC. | $14.50 | 2019 | |
| Upsher-Smith Laboratories LLC | $14.14 | 2019 | |
| Forte Bio-Pharma LLC | $13.86 | 2019 | |
| Kaleo, INC. | $13.79 | 2019 | |
| Biogen, INC. | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.